There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to